Clarity Pharmaceuticals announces early closure of Phase II trial recruitment

Clarity Pharmaceuticals (ASX:CU6) has successfully closed the recruitment for its Phase II diagnostic 4CU-SARTATE trial, DISCO (NCT04438304), ahead of schedule. The trial, aimed at patients with known or suspected neuroendocrine tumours (NETs), enrolled a total of 45 participants, who have all been administered and imaged with 4CU-SARTATE and have progressed to or completed the follow-up stage.

Executive Commentary on DISCO Trial and SARTATE Product

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed satisfaction with the progress of the SARTATE product and the DISCO trial. He highlighted the encouraging initial imaging data in NETs and the potential of SARTATE to improve diagnosis and treatment outcomes for patients. Dr Taylor also emphasized the clinical advantages of SARTATE and the company's focus on developing products for other malignancies with high unmet need.

Summary of Clarity Pharmaceuticals' Phase II Trial and Future Prospects

Clarity Pharmaceuticals (ASX:CU6) has successfully concluded the recruitment for its Phase II diagnostic 4CU-SARTATE trial, DISCO, ahead of schedule. The trial aimed to assess the performance of Clarity's SARTATE imaging product in diagnosing and managing NETs, and the early closure indicates promising progress. Dr Alan Taylor's optimism regarding the final trial results underscores the potential diagnostic capability of 4CU-SARTATE for patients with NETs. The company's focus on developing targeted copper theranostics for the treatment of cancer in children and adults, along with ongoing clinical studies, reflects its commitment to addressing unmet medical needs. Clarity Pharmaceuticals' SARTATE product, if successful, could significantly contribute to improving the diagnosis and treatment outcomes for patients with NETs and other malignancies.